A detailed history of D. E. Shaw & Co., Inc. transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 81,742 shares of AUPH stock, worth $447,128. This represents 0.0% of its overall portfolio holdings.

Number of Shares
81,742
Previous 92,562 11.69%
Holding current value
$447,128
Previous $832,000 50.84%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$4.93 - $9.31 $53,342 - $100,734
-10,820 Reduced 11.69%
81,742 $409,000
Q4 2023

Feb 14, 2024

SELL
$7.13 - $9.49 $1.89 Million - $2.51 Million
-264,584 Reduced 74.08%
92,562 $832,000
Q3 2023

Nov 14, 2023

SELL
$7.77 - $12.27 $1.99 Million - $3.15 Million
-256,367 Reduced 41.79%
357,146 $2.78 Million
Q2 2023

Aug 14, 2023

BUY
$8.96 - $11.69 $970,000 - $1.27 Million
108,259 Added 21.43%
613,513 $5.94 Million
Q1 2023

May 15, 2023

BUY
$5.94 - $11.27 $2.37 Million - $4.5 Million
398,970 Added 375.38%
505,254 $5.54 Million
Q4 2022

Feb 14, 2023

BUY
$4.11 - $8.14 $26,497 - $52,478
6,447 Added 6.46%
106,284 $459,000
Q3 2022

Nov 14, 2022

SELL
$6.66 - $12.39 $91,395 - $170,027
-13,723 Reduced 12.08%
99,837 $751,000
Q2 2022

Aug 15, 2022

BUY
$8.95 - $12.8 $310,090 - $443,481
34,647 Added 43.91%
113,560 $1.14 Million
Q1 2022

May 16, 2022

SELL
$10.05 - $22.48 $1.1 Million - $2.46 Million
-109,420 Reduced 58.1%
78,913 $977,000
Q4 2021

Feb 14, 2022

SELL
$17.78 - $33.08 $2.59 Million - $4.81 Million
-145,536 Reduced 43.59%
188,333 $4.31 Million
Q3 2021

Nov 15, 2021

BUY
$10.93 - $23.55 $3.22 Million - $6.93 Million
294,258 Added 742.87%
333,869 $7.39 Million
Q2 2021

Aug 16, 2021

BUY
$10.0 - $14.52 $277,760 - $403,307
27,776 Added 234.69%
39,611 $513,000
Q1 2021

May 17, 2021

SELL
$12.3 - $18.73 $3.56 Million - $5.42 Million
-289,198 Reduced 96.07%
11,835 $154,000
Q4 2020

Feb 16, 2021

SELL
$12.94 - $16.05 $491,797 - $609,996
-38,006 Reduced 11.21%
301,033 $4.16 Million
Q3 2020

Nov 16, 2020

BUY
$13.19 - $16.66 $2.93 Million - $3.7 Million
222,073 Added 189.86%
339,039 $4.99 Million
Q2 2020

Aug 14, 2020

SELL
$14.12 - $18.33 $80,088 - $103,967
-5,672 Reduced 4.62%
116,966 $1.9 Million
Q1 2020

May 15, 2020

BUY
$11.34 - $21.46 $1.39 Million - $2.63 Million
122,638 New
122,638 $1.78 Million
Q4 2019

Feb 14, 2020

SELL
$3.88 - $21.42 $1.3 Million - $7.18 Million
-335,027 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$5.34 - $6.59 $311,177 - $384,019
-58,273 Reduced 14.82%
335,027 $1.79 Million
Q2 2019

Aug 14, 2019

SELL
$6.05 - $6.75 $937,132 - $1.05 Million
-154,898 Reduced 28.26%
393,300 $2.59 Million
Q1 2019

May 15, 2019

BUY
$6.06 - $7.64 $965,885 - $1.22 Million
159,387 Added 40.99%
548,198 $3.56 Million
Q4 2018

Feb 14, 2019

BUY
$5.08 - $6.83 $634,695 - $853,340
124,940 Added 47.35%
388,811 $2.65 Million
Q3 2018

Nov 14, 2018

BUY
$5.27 - $6.64 $782,062 - $985,369
148,399 Added 128.52%
263,871 $1.75 Million
Q2 2018

Aug 14, 2018

SELL
$5.06 - $6.36 $592,834 - $745,143
-117,161 Reduced 50.36%
115,472 $650,000
Q1 2018

May 15, 2018

BUY
$4.85 - $5.99 $1.13 Million - $1.39 Million
232,633 New
232,633 $1.21 Million

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $776M
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.